CJC-1295

Modified GRF 1-29, CJC-1295 DAC

Growth Hormone Secretagogues

Phase II Clinical

30 views

Overview

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that has been studied for its ability to stimulate growth hormone secretion. It exists in two forms: with and without Drug Affinity Complex (DAC).

Research Summary

CJC-1295 has been studied in human clinical trials for its effects on growth hormone and IGF-1 levels. Research has shown it can significantly increase plasma GH concentrations for extended periods. The DAC version binds to albumin, extending its half-life substantially compared to native GHRH.

Mechanism of Action

CJC-1295 acts as a GHRH analog, binding to GHRH receptors on the anterior pituitary gland to stimulate growth hormone release. The DAC modification allows it to bind to serum albumin, dramatically extending its biological half-life.

Common Discussion Topics

Growth hormone

IGF-1

Body composition

Anti-aging

Metabolism

Dosing Guide

Research-based reference only. Not medical advice. Consult a qualified professional.

Typical Dose0.3 mg (300 mcg)

FrequencyDaily (no DAC) or 1–2x/week (DAC form)

RouteSubcutaneous

CJC-1295 no DAC — Start (Weeks 1–2)0.1 mg (100 mcg)

FrequencyOnce daily (before bed)

RouteSubcutaneous

Duration2 weeks

No DAC form has ~30 min half-life mimicking natural GHRH pulses. Start at 100 mcg. Combine with Ipamorelin for synergistic GH release.

Teichman et al., J Clin Endocrinol Metab 2006 (PMID 16352683) — CJC-1295 pharmacokinetics & GH/IGF-1 elevation in healthy adults

CJC-1295 no DAC — Therapeutic (Weeks 3–12)0.3 mg (300 mcg)

FrequencyOnce daily (before bed, fasted)

RouteSubcutaneous

Duration8–10 weeks

Target 300 mcg/day. The 2006 RCT used 30–60 mcg/kg (≈2–4 mg) for the DAC form; no-DAC dosing is extrapolated from clinical practice.

Teichman et al., J Clin Endocrinol Metab 2006 (PMID 16352683)

CJC-1295 with DAC1 mg (1,000 mcg)

FrequencyOnce or twice weekly

RouteSubcutaneous

Duration8–12 weeks, then 4-week break

DAC form half-life ~5.8–8.1 days. The RCT showed 2- to 10-fold GH increases for 6+ days after a single injection, and sustained IGF-1 elevation above baseline for up to 28 days with multiple doses.

Teichman et al., J Clin Endocrinol Metab 2006 (PMID 16352683)

Phase	Dose	Frequency	Route	Duration	Notes & Sources
CJC-1295 no DAC — Start (Weeks 1–2)	0.1 mg100 mcg	Once daily (before bed)	Subcutaneous	2 weeks	No DAC form has ~30 min half-life mimicking natural GHRH pulses. Start at 100 mcg. Combine with Ipamorelin for synergistic GH release. Teichman et al., J Clin Endocrinol Metab 2006 (PMID 16352683) — CJC-1295 pharmacokinetics & GH/IGF-1 elevation in healthy adults
CJC-1295 no DAC — Therapeutic (Weeks 3–12)	0.3 mg300 mcg	Once daily (before bed, fasted)	Subcutaneous	8–10 weeks	Target 300 mcg/day. The 2006 RCT used 30–60 mcg/kg (≈2–4 mg) for the DAC form; no-DAC dosing is extrapolated from clinical practice. Teichman et al., J Clin Endocrinol Metab 2006 (PMID 16352683)
CJC-1295 with DAC	1 mg1,000 mcg	Once or twice weekly	Subcutaneous	8–12 weeks, then 4-week break	DAC form half-life ~5.8–8.1 days. The RCT showed 2- to 10-fold GH increases for 6+ days after a single injection, and sustained IGF-1 elevation above baseline for up to 28 days with multiple doses. Teichman et al., J Clin Endocrinol Metab 2006 (PMID 16352683)

Frequently Asked Questions

For research purposes only. Not for human consumption.

Related Peptides

Ipamorelin

Growth Hormone Secretagogues

Discussion

Commenting as guest — your email won't be shown publicly.

No comments yet. Be the first to start the discussion!

Stay Updated

Get the latest peptide research insights delivered to your inbox.